Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jul;56(7):777-784.
doi: 10.1007/s00592-019-01310-z. Epub 2019 Mar 22.

Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study

Catharina Busch  1 , Samantha Fraser-Bell  2 , Dinah Zur  3   4 , Patricio J Rodríguez-Valdés  5 , Zafer Cebeci  6 , Marco Lupidi  7 , Adrian T Fung  2   8   9 , Pierre-Henry Gabrielle  10   11 , Ermete Giancipoli  12   13 , Voraporn Chaikitmongkol  14 , Mali Okada  15 , Inês Laíns  16   17   18 , Ana Rita Santos  17   19 , Paradee Kunavisarut  14 , Anna Sala-Puigdollers  20 , Jay Chhablani  21 , Malgorzata Ozimek  22 , Assaf Hilely  3   4 , Jan Darius Unterlauft  23 , Anat Loewenstein  3   4   24 , Matias Iglicki  25 , Matus Rehak  23 ; International Retina Group
Affiliations
Observational Study

Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study

Catharina Busch et al. Acta Diabetol. 2019 Jul.

Abstract

Aims: To describe and compare the functional and anatomical outcomes of untreated and treated diabetic macular edema (DME) in eyes with very good baseline visual acuity (VA) in a real-world setting.

Methods: A 12-month, retrospective, multicenter, observational cohort study, including DME patients with baseline visual acuity (VA) ≤ 0.1 logMAR (≥ 20/25 Snellen) and central subfield thickness (CST) > 250 µm with intra- and/or subretinal fluid seen on optical coherence tomography.

Results: A total of 249 eyes were included, of which 155 were treated and 94 were non-treated during follow-up. Most eyes maintained vision (VA gain or VA loss < 5 letters) at 12 months (treated: 58.1%; non-treated: 73.4%). In non-treated eyes with stable VA within the first 6 months, VA was maintained throughout the follow-up in most cases (86.3%). In non-treated eyes with VA loss ≥ 5 letters within 6 months (36.7%), further observation led to worse visual outcome than treatment (- 4.2 vs. - 7.8 letters, p = 0.013). In eyes in which treatment was initiated at baseline (n = 102), treatment with 8-12 anti-VEGF injections led to better visual outcome compared to treatment with less injections (- 0.3 ± 3.6 letters vs. - 3.8 ± 6.2 letters, p = 0.003).

Conclusion: In a real-world setting, the majority of DME patients with very good VA maintained vision at 12 months, regardless of whether the DME was treated or not. This study supports close observation of eyes with DME and very good VA with consideration of treatment when a one line drop in vision is observed.

Keywords: Anti-VEGF therapy; Diabetic macular edema; Good visual acuity; Intravitreal therapy; Macular laser; Observation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Mean change in visual acuity (a) and central subfield thickness (b, CST) over 12-month follow-up in eyes that were initially non-treated experiencing a VA loss ≥ 5 letters. Data are mean ± 95% confidence interval. M0 baseline, month 0
Fig. 2
Fig. 2
Mean change in visual acuity (a) and central subfield thickness (b, CST) over 12-month follow-up in eyes stratified for number of anti-VEGF injections. Data are mean ± 95% confidence interval. VEGF vascular endothelial growth factor, M0 baseline, month 0
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arroba AI, Valverde AM. Modulation of microglia in the retina: new insights into diabetic retinopathy. Acta Diabetol. 2017;54(6):527–533. doi: 10.1007/s00592-017-0984-z. - DOI - PubMed
    1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi: 10.2337/dc11-1909. - DOI - PMC - PubMed
    1. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi: 10.1016/j.ophtha.2011.12.039. - DOI - PubMed
    1. Diabetic Retinopathy Clinical Research N. Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi: 10.1056/NEJMoa1414264. - DOI - PMC - PubMed
    1. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473–2481. doi: 10.1016/j.ophtha.2014.07.002. - DOI - PubMed

Publication types

MeSH terms